Last updated: February 20, 2026
What Is NDC 00121-0675?
NDC 00121-0675 identifies a specific drug product marketed by AbbVie, primarily known as HUMIRA (adalimumab). Approved by the FDA in 2002, HUMIRA is a monoclonal antibody used to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and plaque psoriasis.
Market Overview
Commercial Landscape
HUMIRA is one of the top-selling biologics globally. In 2022, its global revenue neared $20.6 billion, accounting for approximately 7% of total global biologic sales. Market dominance stems from extensive indications, broad patient acceptance, and widespread geographic penetration.
Key competitors include:
- AbbVie's own Skyrizi (risankizumab)
- Eli Lilly's Taltz (ixekizumab)
- Janssen's Stelara (ustekinumab)
- Novartis's Cosentyx (secukinumab)
Patent and Biosimilar Dynamics
AbbVie's patent protections for HUMIRA expired or are expiring in multiple markets beginning in 2023.
- U.S.: Patents expired in January 2023, opening the market to biosimilars.
- Europe: Patent protection remains until late 2024 or early 2025, depending on country-specific filings.
Biosimilar entries in the U.S. and Europe are projected to increase competition significantly.
Biosimilar Market Entry Timeline
- U.S.: The first adalimumab biosimilars launched in January 2023, with multiple entrants available.
- Europe: Biosimilar approvals began in 2018, with continued expansion.
Impact on Sales and Pricing
Sales are expected to decline sharply in the U.S. over the next 24 months due to biosimilar competition. However, strong continued demand exists in other markets with patent protections.
Price Projection
Pre-Biosimilar Pricing
- Per-syringe wholesale price (U.S. as of 2022): approximately $5,100.
- Annual treatment cost (average patient): $35,000 to $45,000, depending on dosage.
Post-Biosimilar Price Trends
- Initial biosimilar prices: Expected to be 15-30% lower than the reference product.
- Predicted price decline (2023-2025): 20% to 35% reduction on existing list prices, with actual patient out-of-pocket costs decreasing proportionally.
Projected Revenue Decline
| Year |
U.S. Sales Estimate |
Europe & Rest of World |
Comments |
| 2022 |
$20.6 billion |
$4 billion |
Pre-biosimilar peak |
| 2023 |
$12 billion - $14 billion |
$3 billion |
Biosimilar competition begins, decline accelerates |
| 2024 |
$7 billion - $9 billion |
$2 billion |
Continued erosion in U.S., stabilization elsewhere |
| 2025+ |
$3 billion - $5 billion |
$1 billion |
Market stabilization at lower levels |
Long-Term Outlook
The biologic market for adalimumab is facing a structural shift. While the U.S. market declines due to biosimilars, mature markets in Europe and Asia will see gradual erosion, counterbalanced by new indications and improvements in biosimilar acceptance.
Strategic Implications
- For AbbVie: Focus on sustained revenues from emerging indications, combination therapies, and geographic expansion.
- For Investors: Expect revenue compression in the U.S. from 2023 onwards, with diversification necessary in portfolio holdings among biologic assets.
- For Competitors: Biosimilar entrants will capture significant market share; innovation around new biologic formulations or delivery methods may provide differentiation.
Key Takeaways
- NDC 00121-0675 is HUMIRA, a leading biologic with high market penetration.
- Patent expirations in the U.S. and Europe will lead to increased biosimilar competition starting in 2023.
- Biosimilar price reductions will range from 15% to 30%, leading to substantial revenue declines for original manufacturers.
- The U.S. market will see a sharper decline compared to Europe, where patent protections remain longer.
- Revenue from HUMIRA is projected to decrease to $3-5 billion globally by 2025, with a notable shift toward biosimilar reliance.
FAQs
1. How will biosimilar entry affect HUMIRA’s market share in the U.S.?
Biosimilar entrants have captured a substantial share quickly after January 2023, with estimates indicating a 50-60% reduction in HUMIRA’s U.S. sales within the first year.
2. Are there efforts to replace HUMIRA with newer therapies?
Yes. AbbVie and competitors are advancing therapies targeting similar indications, such as Skyrizi, Stelara, and newer JAK inhibitors, to maintain market presence.
3. Will pricing differences be maintained across markets?
Pricing reductions are initially more significant in the U.S., where biosimilar competition is strongest. European markets will retain higher prices until patent expiry or regulatory changes.
4. How do biosimilar pricing trends impact patient costs?
Biosimilar price reductions tend to lower patient copayments and out-of-pocket expenses, though actual savings depend on insurance and healthcare policies.
5. What is the long-term outlook for adalimumab-based therapies?
Market share will decline for original biologics but remain relevant through new indications, formulations, and potential combination therapies that extend product lifecycle.
Citations
- Disease Treatment Market Data (2022). Pharma Intelligence.
- U.S. FDA Biosimilar Approvals (2023). FDA.gov.
- AbbVie Financial Reports (2022). AbbVie Inc..
- European Patent Office Database (2022). EPO.
- MarketWatch: Biologic Drug Pricing (2022). MarketWatch.
